Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 14 Mar 2023
"You can't treat one of these conditions and ignore the others," says the author of the new review, explaining how obesity can affect the diagnosis and treatment of these heart conditions.
Read Full NewsNew findings from the EMBARK study highlight Elevidys' significant long-term benefits in slowing Duchenne muscular dystrophy progression in young patients.
A study of 614 brain donors revealed that individuals with stage III or IV CTE face the greatest risk of dementia.
FDA Approves First Dual-Agent Eye Drop for Near Vision Loss
1.
More pain, more gain? New biopsy technique found to improve prostate cancer detection
2.
AI-based liquid biopsy shows promise for detecting brain cancer
3.
Researchers Challenge USPSTF's Lung Cancer Screening Criteria
4.
When Should Immunocompromised Individuals Receive a COVID Booster?
5.
Added Plinabulin Boosts OS as Later-Line Treatment for EGFR Wild-Type NSCLC
1.
Feline Anemia: Diagnosis and Treatment with Focus on Rasburicase Complications
2.
Revolutionizing Cancer Treatment: Advances in Immunotherapy and Cell Therapy
3.
Advancing Medical Oncology: Education, Certification, Clinical Trials, and Evolving Treatment Pathways
4.
CAR T + Ibrutinib in R/R Mantle Cell Lymphoma: Phase 2 TARMAC Study Insights
5.
Fresh Frozen Plasma: Its Role in Treating Trauma and Bleeding Disorders
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
2.
Current Scenario of Cancer- Palliative Care to Close the Care Gap
3.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II
4.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge